No Data
No Data
Psychedelic Stocks Fall as FDA Panel Rejects MDMA Therapy
FDA Advisory Panel Fails to Endorse Psychedelic MDMA Therapy for PTSD
Psychedelic Stocks Mixed as FDA Comments on MDMA Therapy
Seelos Therapeutics: Offering, Placement Expected to Close Around May 21 >SEEL
Seelos Therapeutics: Offering, Placement Expected to Close Around May 21 >SEEL
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Seelos Therapeutics Shares Are Trading Higher. The Company Announced a 1-for-8 Reverse Stock Split.
Seelos Therapeutics Shares Are Trading Higher. The Company Announced a 1-for-8 Reverse Stock Split.
No Data